GlassScriptPhysician profile
Leslie A Huszar
NPI 1528063492
$2,415.72
in general payments reported to CMS, 2019-2025
22 companies · $874 in 2025
The $874 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $356 · 2023: $350 · 2024: $601 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $433.08 | 2023-2025 | |
| Abbvie INC. | $390.67 | 2022-2025 | |
| Lilly USA, LLC | $387.77 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $166.03 | 2023-2025 | Hyqvia, Gammagard |
| Argenx US, INC. | $149.46 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $143.76 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $110.94 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $80.11 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $69.08 | 2021 | |
| Corium, LLC | $60.83 | 2022-2023 | Adlarity |
| Csl Behring | $49.55 | 2023-2025 | Hizentra |
| Biohaven Pharmaceutical Holding Company LTD. | $48.79 | 2022 | |
| Celgene Corporation | $48.08 | 2024 | Zeposia |
| Biogen, INC. | $47.41 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $46.16 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $35.05 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $29.46 | 2021 | |
| Lundbeck LLC | $29.08 | 2025 | Rexulti |
| Genzyme Corporation | $25.11 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.13 | 2025 | Rexulti |
| Ge Healthcare | $21.17 | 2022 | |
| Impel Pharmaceuticals INC. | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Huszar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.